NCT04529473View on ClinicalTrials.gov

Efficacy and Safety of 12-weeks Supplementation of Eubacterium Hallii on Insulin Sensitivity and Glycaemic Control

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 3, 2021

Primary Completion Date

August 23, 2022

Study Completion Date

August 23, 2022

Conditions
Pre DiabetesImpaired Glucose ToleranceInsulin SensitivityInsulin ResistanceGlucose Metabolism DisordersMetabolic Syndrome
Interventions
DIETARY_SUPPLEMENT

Eubacterium hallii

Eubacterium hallii, ≥ 1x10\^9 live bacterial cells (per capsule)

OTHER

Placebo

Placebo capsules are identical to the active treatment

Trial Locations (3)

60611

Atlantia Food Clinical Trials, Chicago, Chicago

T23 R50R

Atlantia Food Clinical Trials, Cork

G20 0XA

CPS Research, Glasgow

Sponsors

Collaborators (1)

Caelus Pharmaceuticals BV
All Listed Sponsors
collaborator

Caelus Pharmaceuticals BV

INDUSTRY

lead

Atlantia Food Clinical Trials

INDUSTRY

NCT04529473 - Efficacy and Safety of 12-weeks Supplementation of Eubacterium Hallii on Insulin Sensitivity and Glycaemic Control | Biotech Hunter | Biotech Hunter